Metabolic and Longevity Peptides: MOTS-c, SS-31, NAD+, and Retatrutide

The decline in mitochondrial function is one of the most well-documented hallmarks of aging. As mitochondria accumulate damage, produce less ATP, and generate more reactive oxygen species (ROS), cells across every tissue type become less capable of repair, maintenance, and normal function.

Longevity research has increasingly focused on interventions that address metabolic decline upstream — before the downstream consequences (cardiovascular disease, neurodegeneration, metabolic syndrome) become irreversible.

MOTS-c and SS-31 target the mitochondria directly. NAD+ targets the cellular energy sensing and DNA repair machinery that mitochondria depend on. Retatrutide addresses metabolic dysfunction through receptor-mediated hormonal regulation. Together, they represent a comprehensive view of metabolic longevity research targets.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by mitochondrial DNA — not nuclear DNA. This makes it one of only a handful of peptides with mitochondrial origin, and its discovery in 2015 opened a new category of "mitokine" research.

Where it excels: Insulin resistance research, metabolic aging models, exercise physiology, and mitokine pathway research.

SS-31 (also known as Elamipretide or MTP-131) is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds to cardiolipin — a phospholipid critical for mitochondrial structure and function.

Where it excels: Cardiac research, renal protection models, age-related mitochondrial decline, and any model where ROS is a primary endpoint.

NAD+ (Nicotinamide Adenine Dinucleotide) is not a peptide — it is a coenzyme involved in over 500 enzymatic reactions. It is included here because it is functionally inseparable from the mitochondrial and longevity research space.

Where it excels: Sirtuin pathway research, aging biology, DNA repair models, and metabolic disease research. The foundational nature of NAD+ makes it relevant to virtually every longevity research domain.

Retatrutide occupies a completely different mechanistic space from the mitochondria-focused compounds above. It is a triple agonist of GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors — making it the most comprehensive receptor-mediated metabolic research compound available.

Phase 2 clinical data: Retatrutide showed approximately 24% body weight reduction over 48 weeks in Phase 2 trials — the largest weight loss ever recorded for a pharmacological agent in clinical trials.

Where it excels: Obesity research, metabolic syndrome models, liver fat models, and comprehensive metabolic regulation research where all three incretin axes are relevant.

A useful framework for understanding how these compounds relate:

For researchers, this framework suggests combinatorial opportunities: a model that addresses mitochondrial protection (SS-31) alongside systemic metabolic signaling (Retatrutide) is testing different biological layers than a single-compound model. NAD+ as a supporting element in either model addresses the energy substrate availability that both upstream and downstream mechanisms depend on.

All compounds in this group are for laboratory and preclinical research use only. Retatrutide is currently in Phase 3 clinical trials as of 2025 and has no approved therapeutic use. MOTS-c and SS-31 are in earlier clinical development stages. NAD+ and its precursors (NMN, NR) are commercially available as supplements, but research-grade preparations standardized for laboratory use differ from supplement-grade.

For longevity and aging research: Appropriate aging animal models (aged rodents, C. elegans lifespan models, senescent cell models) are critical. These compounds' effects are often most pronounced in aged or metabolically stressed models, with less dramatic effects in young healthy animals.

Purity documentation: For mitochondria-focused research, endotoxin contamination directly activates mitochondrial stress pathways — making high-purity compounds with verified endotoxin testing non-negotiable for valid results.